Agios Pharmaceuticals, Inc. (0HB0.L)
| Chiusura precedente | 27,60 |
| Aperto | 28,30 |
| Denaro | 0,00 x N/D |
| Lettera | 0,00 x N/D |
| Min-Max giorno | 27,05 - 28,30 |
| Intervallo di 52 settimane | 27,05 - 28,30 |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | 12,297M |
| Beta (5 anni mensile) | 1,26 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -6,43 |
| Prossima data utili | 01 nov 2022 - 07 nov 2022 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
Agios Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent α- and β-Thalassemia
– In Adults with Non-transfusion-dependent α- or β-Thalassemia, PYRUKYND® Induced ≥1.0 g/dL Hemoglobin Increase from Baseline in 16 of 20 (80%) Patients Between Weeks 4-12 – – PYRUKYND® Safety Profile Consistent with Label for FDA-approved Indication in Pyruvate Kinase Deficiency – – Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependent α- or β-Thalassemia, Respectively – CAMBRIDGE, Mass., Aug. 11, 2022
- GlobeNewswire
ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox
Maraganore brings more than 35 years of scientific, research and development, capital markets and managerial leadership expertise to ProKidney Fox joins Board with more than 25 years of healthcare investment banking, finance and capital markets experience WINSTON-SALEM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (“CKD”), today announce
- GlobeNewswire
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Executive Officer
CAMBRIDGE, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today announced the grant of inducement equity awards outside of the company’s 2013 Stock Incentive Plan to its newly appointed chief executive officer, Brian Goff. The grants were approved by the board of directors effective as of August 8, 2022 as inducements material to Mr. Goff entering into employm
